Leveraging the Capabilities of Gamma Delta T Cells: Sebastian Wanless, MD, PhD

Video

Sebastian Wanless, MD, PhD, senior clinical director of TC BioPharm, joins CGTL to discuss the company's development of chimeric co-stimulatory receptor T cells, as well as its clinical programs targeting cancers and infectious diseases.

"As far as I'm aware, this is unique. The are no other companies or researchers that we know of who have developed a product where the CAR only has the co-stimulatory domain." —Sebastian Wanless, MD, PhD, senior clinical director of TC BioPharm

The FDA recently granted orphan drug designation to TC BioPharm for its unmodified allogeneic gamma delta T cell (GDT) product TCB-002 (OmnImmune) for the potential treatment of relapsed/refractory acute myeloid leukemia (AML).

The UK-based cell therapy company, which applies chimeric antigen receptor (CAR) T-cell technology to GDT cells in an effort to make the therapeutic more selective, is also moving toward clinical trials for treatments for a range of cancers, as well as infectious diseases.

Joining CGTL to discuss updates on its clinical programs is Sebastian Wanless, MD, PhD, senior clinical director of TC BioPharm.

Recent Videos
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Peter Cook, PhD, a senior research scientist at Seattle Children’s Research Institute
Nicholas Giovannone, PhD, a senior principal scientist at Regeneron
Related Content
© 2025 MJH Life Sciences

All rights reserved.